Suite 1300
Salt Lake City, UT 84111
Block-1 3rd Floor, Perungudi Bypass Rd, Perungudi,
Chennai - 600096
MGR Main Rd,
Perungudi, Chennai - 600096
Villupuram,
Tamil Nadu – 605602
Buy-and-bill Operations
Buy-and-Bill Operations Built for the Cash and Inventory Risk This Model Actually Carries
End-to-end buy-and-bill workflow for physician offices, infusion centers, and hospital outpatient settings — inventory acquisition, J-code billing, payer reimbursement reconciliation, and the cash flow and inventory risk management discipline buy-and-bill economics actually require.
98%+
J-Code Billing
Accuracy
95%+
Inventory-to-Reimbursement
Reconciliation
30–50%
Reduction in Revenue
Leakage
The Reality
Why Buy-and-Bill carries inventory and cash flow risk that specialty pharmacy operations routinely underestimate?
Buy-and-bill — the model where providers purchase specialty medications, dispense them in the office or infusion center, and bill payers under medical benefit (typically J-codes) — looks simple on the surface but carries inventory acquisition risk, cash flow lag, and reimbursement reconciliation complexity that distinguishes it from standard pharmacy dispensing. A single high-cost biologic represents real working capital tied up between purchase and reimbursement. without dedicated reconciliation discipline absorb inventory losses, reimbursement gaps, and cash flow strain quietly.
Inventory Working Capital Risk
Buy-and-bill providers purchase specialty inventory at WAC pricing — often $5,000–$50,000+ per dose. Reimbursement arrives 30-90 days after dispensing. The working capital lag at scale is substantial, and inventory that can't be billed (eligibility issues, PA denials, patient no-shows) becomes direct loss rather than write-off.
J-Code Billing Specificity
Buy-and-bill claims route through medical benefit on 837 claims with HCPCS J-codes, units calculation, modifier requirements, and site-of-service distinctions. Coding errors create denial volume that's harder to recover than NCPDP pharmacy denials — and the per-claim dollar exposure is substantially higher.
Payer Reimbursement Variability
The same J-code reimburses differently across Medicare Part B, Medicare Advantage, commercial plans, Medicaid, and managed Medicaid. Reimbursement reconciliation against expected payer rates requires payer-specific contract intelligence that most provider operations don't maintain.
340B Inventory Logic at Buy-and-Bill
For 340B-participating providers, buy-and-bill inventory must be routed through 340B procurement when patient encounters qualify. Mixed-use inventory accounting at buy-and-bill (340B-eligible patients dispensed alongside non-340B-eligible patients from the same vial) requires inventory accounting infrastructure that goes well beyond standard buy-and-bill.
Patient No-Show Inventory Loss
Specialty infusion appointments scheduled around expensive pre-purchased inventory carry no-show risk. When patients don't show, the inventory either gets used for another patient (requiring reconciliation), gets stored for future use (carrying expiration risk), or gets discarded (creating direct loss). Operations without no-show inventory protocols absorb these losses.
Reimbursement-to-Inventory Reconciliation
The buy-and-bill economic model only works when each unit of purchased inventory translates to corresponding billed and reimbursed claims. Reconciliation gaps — purchased units that don't appear in billing, billed units that don't reconcile to dispensing, reimbursed claims that don't reconcile to inventory consumption — quietly erode buy-and-bill margins.
Our approach
We run buy-and-bill as inventory-aware reconciliation operations
AnnexMed runs buy-and-bill operations as dedicated inventory-aware capability — with J-code billing accuracy across payer types, inventory-to-reimbursement reconciliation, working capital cash flow tracking, 340B inventory routing logic, no-show inventory protocols, and payer-specific reimbursement rate intelligence. Buy-and-bill becomes a managed economic model with inventory discipline matching reimbursement discipline.
We serve specialty pharmacies, infusion centers, oncology practices, rheumatology practices, hospital outpatient settings, and other provider environments operating buy-and-bill economics. Our team manages buy-and-bill across Medicare Part B, Medicare Advantage, commercial plans, Medicaid, and managed Medicaid — with payer-specific reimbursement intelligence and inventory reconciliation built into every workflow.
Recent client results
An infusion center serving 320 active oncology and immunology patients improved buy-and-bill J-code claim accuracy from 88% to 98.4% within 90 days of go-live, recovering approximately $1.6M in annual reimbursement that had been lost to coding errors. A rheumatology practice operating substantial biologic buy-and-bill volume reduced average inventory-to-reimbursement cycle from 67 days to 38 days through coordinated billing acceleration — recovering an estimated $720,000 in working capital. A 340B-participating infusion center identified $480,000 in annual mixed-use inventory accounting gaps where 340B-eligible patient encounters had not routed through 340B procurement correctly.
98%+
J-Code Billing Accuracy
< 40 days
Inventory-to-Reimbursement Cycle
Mixed-Use
340B Accounting Standard
How we support you
End-to-End buy-and-bill operation
AnnexMed runs buy-and-bill operations as a three-stage discipline — J-code billing accuracy and payer-specific reimbursement intelligence, inventory-to-reimbursement reconciliation with working capital tracking, and 340B mixed-use accounting where applicable — so buy-and-bill becomes a managed economic model with the operational discipline its inventory and cash flow risk actually require.
J-Code Billing
Medical benefit accuracy
- HCPCS J-code selection and validation
- Units calculation accuracy
- Modifier and site-of-service requirements
- Payer-specific J-code edits
- Medicare Part B, MA, commercial, Medicaid routing
- 837 medical claim submission
Inventory Reconciliation
Cash flow and working capital
- Inventory acquisition tracking
- Inventory-to-dispensing reconciliation
- Dispensing-to-billing reconciliation
- Billing-to-reimbursement reconciliation
- Working capital cycle tracking
- No-show inventory protocol management
340B Mixed-Use
When applicable for 340B providers
- 340B-eligible patient encounter routing
- Mixed-use inventory accounting
- 340B procurement coordination
- Non-340B inventory accounting
- Mixed-use reconciliation workflow
- Audit-ready 340B documentation
Financial impact
What buy-and-bill discipline means in dollars?
For an infusion center, oncology practice, rheumatology practice, or hospital outpatient setting operating substantial buy-and-bill volume, dedicated buy-and-bill operations regularly deliver $800K–$3M+ in net annual financial benefit through J-code billing accuracy improvement, inventory-to-reimbursement reconciliation, working capital cycle compression, and 340B mixed-use accounting where applicable. Most providers achieve full ROI on buy-and-bill operations within 5–7 months.
Fast Results
Built for Cash Flow Reality
Improvement Area
Estimated Annual Impact
J-Code Billing Accuracy Recovery (88% → 98.4%)
$600K – $1.8M annually in correctly billed claims
Inventory-to-Reimbursement Cycle Acceleration (67 → 38 days)
$400K – $1.2M annually in freed working capital
340B Mixed-Use Accounting Capture
$200K – $700K annually for 340B-participating providers
No-Show Inventory Loss Prevention
$100K – $400K annually in protected inventory
Payer-Specific Reimbursement Rate Recovery
$150K – $500K annually in underpaid claim recovery
Reconciliation Gap Discovery
$120K – $400K annually in surfaced unbilled inventory
Staffing Cost Reduction / Replacement
$180K – $450K annually
Buy-and-bill performance targets
Performance Metric
Industry Benchmark
AnnexMed Target
J-Code Billing Accuracy
Industry avg: 84–90%
98%+
Inventory-to-Reimbursement Cycle
Industry avg: 60–90 days
< 40 days
Inventory-to-Dispensing Reconciliation
Industry avg: 88–94%
99%+
340B Mixed-Use Accounting
Industry: often missed
Standard for 340B providers
No-Show Inventory Protocol Coverage
Industry: variable
Standard practice
Payer-Specific Reimbursement Intelligence
Most operations cover 6–10 payers
Top 40 payers
Working Capital Cycle Tracking
Industry: quarterly retrospective
Real-time
Reconciliation Cadence
Industry standard: Weekly or monthly
Daily
Why Annexmed?
Generic buy-and-bill vs. AnnexMed inventory-aware operation
In-House / Traditional
AnnexMed Partnership
J-Code Billing Accuracy
84–90% on first-pass
98%+ with payer-specific edits
Inventory Reconciliation
Periodic spot-checks
Daily inventory-to-dispensing-to-billing reconciliation
Working Capital Tracking
Quarterly retrospective
Real-time cycle tracking with cash flow discipline
340B Mixed-Use Accounting
Often missed for 340B providers
Standard mixed-use accounting workflow
No-Show Inventory Protocols
Reactive after losses accumulate
Standard no-show inventory protocol management
Payer Reimbursement Intelligence
Top 6–10 payers
Top 40 payer-specific reimbursement intelligence
Reconciliation Cadence
Weekly or monthly
Daily reconciliation across the buy-and-bill chain
Cost to Operate
$80K–$115K per FTE for buy-and-bill specialist
30–40% lower with no hiring, attrition, or training overhead
Technology
Powered by proprietary AI & analytics
AnnexMed’s technology stack was built for payer-specific operational demands, not adapted from provider-side billing tools. Risk adjustment accuracy, payment integrity, and credentialing compliance each require different data models, workflow logic, and reporting architectures than provider RCM. Our platform reflects that.
AI Agents & Automation
AI Agents & Intelligent Automation deploys autonomous AI agents across the full revenue cycle, automating eligibility verification, prior authorization, claims processing, payment posting, and denial management at hospital scale and speed.
Data & Analytics Platform
Data & Analytics Platform delivers real-time Power BI dashboards built for hospital executive visibility, including system-wide KPIs, service line performance, payer analysis, productivity, financial forecasting, and national benchmarking insights.
Intelligent AR Management
Intelligent AR Management handles A/R follow-up at hospital scale with intelligent worklists prioritized by dollar value and aging, payer-specific follow-up rules, automated escalation for high-value accounts, and full accountability for every claim.
Computer Assisted Coding
Computer Assisted Coding orchestrates hospital coding operation, intelligent chart assignment by service line, TAT tracking with SLA monitoring, quality audits with accuracy scoring, and coder performance management at enterprise scale.
Together, these platforms create a fully instrumented RCM operation where nothing falls through the cracks. You don’t interact with these systems directly, but the results they enable show up directly in your financial performance.
Ready to run buy-and-bill as a managed economic model instead of an inventory-risk black box?
Trusted by 100+ Healthcare Providers | AAPC, AHIMA & AAHAM Certified | SOC 2 Type II | HIPAA Compliant
Payer client outcomes
$15M–$40M
Risk
Adjustment
$18M–$50M
Payment
Integrity
6 Weeks
Credentialing Clearance
$15M–$50M+
Revenue
Impact
Case Studies
See the impact we deliver
Discover how AnnexMed reduces denials, accelerates reimbursements, and strengthens financial performance. Backed by measurable outcomes and proven RCM expertise, we deliver operational excellence, revenue stability, and sustainable growth you can trust.
Client Voices
See how our clients succeed
Proven RCM expertise. Delivered at scale.
For over 20 years, AnnexMed has delivered RCM solutions nationwide, combining expert billing, coding, and AR support to drive measurable results and growth.
- 20+ years of proven healthcare RCM experience
- 1,500+ professionals supporting billing, coding & AR
- 500+ certified coders across multiple specialties
- 99%+ compliance with HIPAA and security standards
- All 50 states served with consistent, scalable operations
